HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.

Abstract
Neuronal dysfunction and demise together with a reduction in neurogenesis are cardinal features of Alzheimer's disease (AD) induced by a combination of oxidative stress, toxic amyloidpeptide (Aβ) and a loss of trophic factor support. Amelioration of these was assessed with the Aβ lowering AD experimental drugs (+)-phenserine and (-)-phenserine in neuronal cultures, and actions in mice were evaluated with (+)-phenserine. Both experimental drugs together with the metabolite N1-norphenserine induced neurotrophic actions in human SH-SY5Y cells that were mediated by the protein kinase C (PKC) and extracellular signal-regulated kinases (ERK) pathways, were evident in cells expressing amyloid precursor protein Swedish mutation (APP(SWE)), and retained in the presence of Aβ and oxidative stress challenge. (+)-Phenserine, together with its (-) enantiomer as well as its N1- and N8-norphenserine and N1,N8-bisnorphenserine metabolites, likewise provided neuroprotective activity against oxidative stress and glutamate toxicity via the PKC and ERK pathways. These neurotrophic and neuroprotective actions were evident in primary cultures of subventricular zone (SVZ) neural progenitor cells, whose neurosphere size and survival were augmented by (+)-phenserine. Translation of these effects in vivo was assessed in wild type and AD APPswe transgenic (Tg2576) mice by doublecortin (DCX) immunohistochemical analysis of neurogenesis in the SVZ, which was significantly elevated by 16 day systemic (+)-phenserine treatment, in the presence of a (+)-phenserine-induced elevation in brain- derived neurotrophic factor (BDNF).
AuthorsAnna M Lilja, Yu Luo, Qian-sheng Yu, Jennie Röjdner, Yazhou Li, Ann M Marini, Amelia Marutle, Agneta Nordberg, Nigel H Greig
JournalPloS one (PLoS One) Vol. 8 Issue 1 Pg. e54887 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID23382994 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Dcx protein, mouse
  • Doublecortin Protein
  • Neuroprotective Agents
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • Physostigmine
  • phenserine
Topics
  • Alzheimer Disease (drug therapy)
  • Amyloid beta-Peptides (pharmacology)
  • Amyloid beta-Protein Precursor (genetics, metabolism)
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Dose-Response Relationship, Drug
  • Doublecortin Protein
  • Drug Discovery
  • Gene Expression Regulation (drug effects)
  • Humans
  • Mice
  • Mice, Transgenic
  • Mutation
  • Neural Stem Cells (cytology, drug effects, metabolism)
  • Neurons (cytology, drug effects, metabolism)
  • Neuroprotective Agents (chemistry, pharmacology, therapeutic use)
  • Oxidative Stress (drug effects)
  • Peptide Fragments (pharmacology)
  • Physostigmine (analogs & derivatives, chemistry, pharmacology, therapeutic use)
  • Stereoisomerism

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: